Latest Investigation News

QPM Energy Ltd has entered voluntary administration with receivers appointed to its gas assets. Operations continue while administrators prepare for a sale or recapitalisation process, with creditor meetings extended to early 2027.

Enova Mining has delivered robust rare earth element assay results across multiple Brazilian projects, confirming extensive ionic adsorption clay mineralisation and advancing metallurgical test work, while also reporting promising drilling outcomes in Australia’s Northern Territory.

Excite Technology Services lifted customer receipts by 24% to $4.91 million in the June quarter, slashing its net operating cash outflow to just $112K. The company also secured a $3.5 million placement to bolster its sales and product efforts.

Fatfish Group disclosed its Q2 CY2025 financials with modest cash receipts and divestment proceeds while continuing to probe alleged improper conduct by a former consultant, leaving the company’s financial impact unresolved.

Foresta Group Holdings progresses its Kawerau Stage 1 project with major engineering milestones, secures a NZD$35,000 Ara Ake grant for technology review, and obtains US patent allowance for its rosin and terpene production process.

Clarity Pharmaceuticals bolsters its commercial readiness with a $178.3 million cash reserve and a key US manufacturing agreement, while clinical trials for its prostate cancer imaging and therapeutic agents progress with promising data.

Northern Minerals propels its Browns Range Heavy Rare Earths Project forward with a planned Final Investment Decision in Q3 2026 and a significant 40% increase in the Dazzler Deposit resource.

Neurotech International has secured FDA clearance for its NTI164 Investigational New Drug application and obtained Notices of Allowance for two US patents, advancing its Phase 3 autism spectrum disorder program.

VBX Limited has secured crucial environmental approvals to optimise its Wuudagu bauxite project and signed a $10 million indicative prepayment and offtake facility, alongside a framework agreement with a major Chinese aluminium group, amid robust market demand.

Zelira Therapeutics has raised nearly US$33 million into its HOPE® 1 special purpose vehicle, valuing the SPV at about US$66 million post-money. The funds will advance FDA regulatory submissions and Phase 1 clinical trials for its autism-targeting cannabinoid drug.

Mesoblast delivered US$115 million in Ryoncil® revenue in its first full year post-FDA approval, while expanding clinical trials into adult indications and acquiring cutting-edge CAR technology to boost its cell therapy pipeline.

Island Pharmaceuticals has marked a major step forward in its antiviral program with the start of GMP manufacturing for Galidesivir, expanded USAMRIID collaboration, and FDA orphan drug designation. Regulatory approvals for compassionate use in Uganda’s Ebola outbreak and a new dose optimisation study with Texas Biomed further de-risk the pathway to approval.